HIV skews the SARS-CoV-2 B cell response toward an extrafollicular maturation pathway

  1. Robert Krause  Is a corresponding author
  2. Jumari Snyman
  3. Hwa Shi-Hsia
  4. Daniel Muema
  5. Farina Karim
  6. Yashica Ganga
  7. Abigail Ngoepe
  8. Yenzekile Zungu
  9. Inbal Gazy
  10. Mallory Bernstein
  11. Khadija Khan
  12. Matilda Mazibuko
  13. Ntombifuthi Mthabela
  14. Dirhona Ramjit
  15. COMMIT-KZN Team
  16. Oliver Limbo
  17. Joseph Jardine
  18. Devin Sok
  19. Ian A Wilson
  20. Willem Hanekom
  21. Alex Sigal
  22. Henrik Kløverpris
  23. Thumbi Ndung'u
  24. Alasdair Leslie
  1. Africa Health Research Institute, South Africa
  2. University of KwaZulu-Natal, South Africa
  3. International AIDS Vaccine Initiative, United States
  4. Scripps Research Institute, United States

Abstract

Background: HIV infection dysregulates the B cell compartment, affecting memory B cell formation and the antibody response to infection and vaccination. Understanding the B cell response to SARS-CoV-2 in people living with HIV (PLWH) may explain the increased morbidity, reduced vaccine efficacy, reduced clearance, and intra-host evolution of SARS-CoV-2 observed in some HIV-1 coinfections.

Methods: We compared B cell responses to COVID-19 in PLWH and HIV negative (HIV-ve) patients in a cohort recruited in Durban, South Africa, during the first pandemic wave in July 2020 using detailed flow cytometry phenotyping of longitudinal samples with markers of B cell maturation, homing and regulatory features.

Results: This revealed a coordinated B cell response to COVID-19 that differed significantly between HIV-ve and PLWH. Memory B cells in PLWH displayed evidence of reduced germinal center (GC) activity, homing capacity and class-switching responses, with increased PD-L1 expression, and decreased Tfh frequency. This was mirrored by increased extrafollicular (EF) activity, with dynamic changes in activated double negative (DN2) and activated naïve B cells, which correlated with anti-RBD-titres in these individuals. An elevated SARS-CoV-2 specific EF response in PLWH was confirmed using viral spike and RBD bait proteins.

Conclusions: Despite similar disease severity, these trends were highest in participants with uncontrolled HIV, implicating HIV in driving these changes. EF B cell responses are rapid but give rise to lower affinity antibodies, less durable long-term memory, and reduced capacity to adapt to new variants. Further work is needed to determine the long-term effects of HIV on SARS-CoV-2 immunity, particularly as new variants emerge.

Funding: This work was supported by a grant from the Wellcome Trust to the Africa Health Research Institute (Wellcome Trust Strategic Core Award [grant number 201433/Z/16/Z]). Additional funding was received from the South African Department of Science and Innovation through the National Research Foundation (South African Research Chairs Initiative, [grant number 64809]), and the Victor Daitz Foundation.

Data availability

All data generated or analyzed during this study are included in the manuscript and Source data 1.

Article and author information

Author details

  1. Robert Krause

    Africa Health Research Institute, Durban, South Africa
    For correspondence
    robert.krause@ahri.org
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1558-0397
  2. Jumari Snyman

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  3. Hwa Shi-Hsia

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  4. Daniel Muema

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  5. Farina Karim

    School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9698-016X
  6. Yashica Ganga

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  7. Abigail Ngoepe

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  8. Yenzekile Zungu

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  9. Inbal Gazy

    KwaZulu-Natal Research Innovation and Sequencing Platform, University of KwaZulu-Natal, Durban, South Africa
    Competing interests
    No competing interests declared.
  10. Mallory Bernstein

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  11. Khadija Khan

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7565-7400
  12. Matilda Mazibuko

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  13. Ntombifuthi Mthabela

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  14. Dirhona Ramjit

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  15. COMMIT-KZN Team

  16. Oliver Limbo

    International AIDS Vaccine Initiative, New York, United States
    Competing interests
    No competing interests declared.
  17. Joseph Jardine

    International AIDS Vaccine Initiative, New York, United States
    Competing interests
    No competing interests declared.
  18. Devin Sok

    International AIDS Vaccine Initiative, New York, United States
    Competing interests
    No competing interests declared.
  19. Ian A Wilson

    Scripps Research Institute, La Jolla, United States
    Competing interests
    No competing interests declared.
  20. Willem Hanekom

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  21. Alex Sigal

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    Alex Sigal, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8571-2004
  22. Henrik Kløverpris

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
  23. Thumbi Ndung'u

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2962-3992
  24. Alasdair Leslie

    Africa Health Research Institute, Durban, South Africa
    Competing interests
    No competing interests declared.

Funding

Wellcome Trust (201433/Z/16/Z)

  • Alex Sigal

National Research Foundation (64809)

  • Alex Sigal

Victor Daitz Foundation

  • Alex Sigal

Max Planck Institute for Infection Biology (open access funding)

  • Alex Sigal

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The study protocol was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (approval BREC/00001275/2020). Written informed consent was obtained for all enrolled participants.

Reviewing Editor

  1. Bavesh D Kana, University of the Witwatersrand, South Africa

Publication history

  1. Received: May 3, 2022
  2. Preprint posted: June 15, 2022 (view preprint)
  3. Accepted: October 23, 2022
  4. Accepted Manuscript published: October 27, 2022 (version 1)
  5. Version of Record published: November 8, 2022 (version 2)

Copyright

© 2022, Krause et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 456
    Page views
  • 131
    Downloads
  • 1
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Robert Krause
  2. Jumari Snyman
  3. Hwa Shi-Hsia
  4. Daniel Muema
  5. Farina Karim
  6. Yashica Ganga
  7. Abigail Ngoepe
  8. Yenzekile Zungu
  9. Inbal Gazy
  10. Mallory Bernstein
  11. Khadija Khan
  12. Matilda Mazibuko
  13. Ntombifuthi Mthabela
  14. Dirhona Ramjit
  15. COMMIT-KZN Team
  16. Oliver Limbo
  17. Joseph Jardine
  18. Devin Sok
  19. Ian A Wilson
  20. Willem Hanekom
  21. Alex Sigal
  22. Henrik Kløverpris
  23. Thumbi Ndung'u
  24. Alasdair Leslie
(2022)
HIV skews the SARS-CoV-2 B cell response toward an extrafollicular maturation pathway
eLife 11:e79924.
https://doi.org/10.7554/eLife.79924

Further reading

    1. Epidemiology and Global Health
    Peter Bruun-Rasmussen, Morten Hanefeld Dziegiel ... Søren Brunak
    Research Article Updated

    Background:

    Whether natural selection may have attributed to the observed blood group frequency differences between populations remains debatable. The ABO system has been associated with several diseases and recently also with susceptibility to COVID-19 infection. Associative studies of the RhD system and diseases are sparser. A large disease-wide risk analysis may further elucidate the relationship between the ABO/RhD blood groups and disease incidence.

    Methods:

    We performed a systematic log-linear quasi-Poisson regression analysis of the ABO/RhD blood groups across 1,312 phecode diagnoses. Unlike prior studies, we determined the incidence rate ratio for each individual ABO blood group relative to all other ABO blood groups as opposed to using blood group O as the reference. Moreover, we used up to 41 years of nationwide Danish follow-up data, and a disease categorization scheme specifically developed for diagnosis-wide analysis. Further, we determined associations between the ABO/RhD blood groups and the age at the first diagnosis. Estimates were adjusted for multiple testing.

    Results:

    The retrospective cohort included 482,914 Danish patients (60.4% females). The incidence rate ratios (IRRs) of 101 phecodes were found statistically significant between the ABO blood groups, while the IRRs of 28 phecodes were found statistically significant for the RhD blood group. The associations included cancers and musculoskeletal-, genitourinary-, endocrinal-, infectious-, cardiovascular-, and gastrointestinal diseases.

    Conclusions:

    We found associations of disease-wide susceptibility differences between the blood groups of the ABO and RhD systems, including cancer of the tongue, monocytic leukemia, cervical cancer, osteoarthrosis, asthma, and HIV- and hepatitis B infection. We found marginal evidence of associations between the blood groups and the age at first diagnosis.

    Funding:

    Novo Nordisk Foundation and the Innovation Fund Denmark

    1. Epidemiology and Global Health
    2. Genetics and Genomics
    Peh Joo Ho, Iain BeeHuat Tan ... Jingmei Li
    Research Article

    Background: To evaluate the utility of polygenic risk scores (PRS) in identifying high-risk individuals, different publicly available PRS for breast (n=85), prostate (n=37), colorectal (n=22) and lung cancers (n=11) were examined in a prospective study of 21,694 Chinese adults.

    Methods: We constructed PRS using weights curated in the online PGS Catalog. PRS performance was evaluated by distribution, discrimination, predictive ability, and calibration. Hazard ratios (HR) and corresponding confidence intervals [CI] of the common cancers after 20 years of follow-up were estimated using Cox proportional hazard models for different levels of PRS.

    Results: A total of 495 breast, 308 prostate, 332 female-colorectal, 409 male-colorectal, 181 female-lung and 381 male-lung incident cancers were identified. The area under receiver operating characteristic curve for the best performing site-specific PRS were 0.61 (PGS000873, breast), 0.70 (PGS00662, prostate), 0.65 (PGS000055, female-colorectal), 0.60 (PGS000734, male-colorectal) and 0.56 (PGS000721, female-lung), and 0.58 (PGS000070, male-lung), respectively. Compared to the middle quintile, individuals in the highest cancer-specific PRS quintile were 64% more likely to develop cancers of the breast, prostate, and colorectal. For lung cancer, the lowest cancer-specific PRS quintile was associated with 28-34% decreased risk compared to the middle quintile. In contrast, the hazard ratios observed for quintiles 4 (female-lung: 0.95 [0.61-1.47]; male-lung: 1.14 [0.82-1.57]) and 5 (female-lung: 0.95 [0.61-1.47]) were not significantly different from that for the middle quintile.

    Conclusions: Site-specific PRSs can stratify the risk of developing breast, prostate, and colorectal cancers in this East Asian population. Appropriate correction factors may be required to improve calibration.

    Funding This work is supported by the National Research Foundation Singapore (NRF-NRFF2017-02), PRECISION Health Research, Singapore (PRECISE) and the Agency for Science, Technology and Research (A*STAR). WP Koh was supported by National Medical Research Council, Singapore (NMRC/CSA/0055/2013). CC Khor was supported by National Research Foundation Singapore (NRF-NRFI2018-01). Rajkumar Dorajoo received a grant from the Agency for Science, Technology and Research Career Development Award (A*STAR CDA - 202D8090), and from Ministry of Health Healthy Longevity Catalyst Award (HLCA20Jan-0022). The Singapore Chinese Health Study was supported by grants from the National Medical Research Council, Singapore (NMRC/CIRG/1456/2016) and the U.S. National Institutes of Health [NIH] (R01 CA144034 and UM1 CA182876).